Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-BN-RSV Phase 1 Trial (Intranasal/Intramuscular)
NCT02864628Phase 1Withdrawn
- Sponsor
- Bavarian Nordic
- Start
- Sep 2016
- Primary completion
- Oct 2017
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial of MVA-BN-RSV in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Bavarian Nordic. Primary endpoint: Occurrence of serious adverse events. Planned start Sep 2016; status: withdrawn.
02
Drugs
MVA-BN-RSV
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02864628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864628.